An Unmet Need
Cachexia has been recognised for a long time as an adverse effect of cancer. It is associated with reduced physical function, reduced tolerance to anticancer therapy, and reduced survival.
Cancer patients with muscle wasting are less able to tolerate chemotherapy, have worse treatment outcomes, loss of independence and shorter overall survival.
Thus, cachexia represents an important unmet medical need.
Actimed Therapeutics aims to be the first company to successfully develop an anti-cachexia drug.